Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimised high-dose dual therapy vs bismuth quadruple therapy for first-line Helicobacter pylori eradication
ChiCTR2000039096Phase 4Recruiting
- Sponsor
- PLA Army Specialty Medical Center
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of amoxicillin, metronidazole and bismuth subsalicylate in Helicobacter pylori infection, chronic gastritis and Peptic ulcer disease (PUD) (2 arms), sponsored by PLA Army Specialty Medical Center. Primary endpoint: eradication rate. Started Oct 2020; status: recruiting.
02
Drugs
amoxicillinmetronidazolebismuth subsalicylate
03
Conditions
Helicobacter pylori infectionchronic gastritisPeptic ulcer disease (PUD)
Beyond the preview
Go deeper on ChiCTR2000039096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039096.